{"event":"metabolic-medicine-tracker","title":"GLP-1 and metabolic medicine tracker","state":"developing","updated":"2026-10-10T00:00:00.000Z","entries":[{"id":"kjx5b2","at":"2026-10-01T00:00:00.000Z","title":"Survodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJM","status":"confirmed","cites":[{"id":"metabolic-medicine-synchronize2-result","n":23,"url":"https://doi.org/10.1056/NEJMoa2607219","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"1hunvk4","at":"2026-09-30T00:00:00.000Z","title":"ACHIEVE-4 shows orforglipron is non-inferior to insulin glargine on heart events","status":"confirmed","cites":[{"id":"metabolic-medicine-achieve4-result","n":21,"url":"https://doi.org/10.1016/S0140-6736(26)01865-9","publisher":"The Lancet","short":"The Lancet"},{"id":"metabolic-medicine-achieve4-safety","n":50,"url":"https://doi.org/10.1016/S0140-6736(26)01865-9","publisher":"The Lancet","short":"The Lancet"}]},{"id":"1lt64w6","at":"2026-09-30T00:00:00.000Z","title":"Lilly reports EloraTZP (eloralintide plus tirzepatide) phase 2b results (company data)","status":"reported","cites":[{"id":"metabolic-medicine-eloratzp-phase2","n":24,"url":"https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html","publisher":"Eli Lilly and Company (press release via PR Newswire)","short":"Eli Lilly and Company"}]},{"id":"44apkg","at":"2026-09-29T00:00:00.000Z","title":"Full TRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) retatrutide results published","status":"confirmed","cites":[{"id":"metabolic-medicine-triumph1-nejm","n":5,"url":"https://doi.org/10.1056/NEJMoa2604169","publisher":"The New England Journal of Medicine","short":"The New England Journal…"},{"id":"metabolic-medicine-triumph1-oa-osa","n":17,"url":"https://doi.org/10.1056/NEJMoa2604169","publisher":"The New England Journal of Medicine","short":"The New England Journal…"},{"id":"metabolic-medicine-triumph2-result","n":18,"url":"https://doi.org/10.1016/S0140-6736(26)01861-1","publisher":"The Lancet","short":"The Lancet"}]},{"id":"t5qxsf","at":"2026-09-24T00:00:00.000Z","title":"FDA approves Lilly's once-weekly insulin Onswik","status":"confirmed","cites":[{"id":"metabolic-medicine-onswik-approval","n":49,"url":"https://www.prnewswire.com/news-releases/us-food-and-drug-administration-fda-approves-lillys-onswik-insulin-efsitora-alfa-gobe-a-once-weekly-basal-insulin-injection-treatment-for-adults-living-with-type-2-diabetes-302888473.html","publisher":"Eli Lilly and Company (press release via PR Newswire)","short":"Eli Lilly and Company"}]},{"id":"199rvso","at":"2026-09-21T00:00:00.000Z","title":"Novo reports CagriSema beat tirzepatide 5 mg in REIMAGINE 5 (company topline)","status":"reported","cites":[{"id":"metabolic-medicine-reimagine5-redefine9","n":22,"url":"https://www.nasdaq.com/press-release/novos-cagrisema-delivers-superior-weight-loss-versus-tirzepatide-reimagine-5-trial","publisher":"Novo Nordisk (press release via Nasdaq)","short":"Novo Nordisk"}]},{"id":"1i3hhj7","at":"2026-08-28T00:00:00.000Z","title":"FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetes (Lilly announcement)","status":"confirmed","cites":[{"id":"metabolic-medicine-mounjaro-cv-approval","n":20,"url":"https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html","publisher":"Eli Lilly and Company (press release via PR Newswire)","short":"Eli Lilly and Company"},{"id":"metabolic-medicine-surpass-cvot-result","n":48,"url":"https://europepmc.org/article/MED/41406444","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"a9mwuw","at":"2026-08-12T00:00:00.000Z","title":"Lilly sues black-market retatrutide sellers, stressing no approved product exists","status":"confirmed","cites":[{"id":"metabolic-medicine-retatrutide-black-market","n":47,"url":"https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html","publisher":"Eli Lilly and Company (press release via PR Newswire)","short":"Eli Lilly and Company"}]},{"id":"t15vn4","at":"2026-08-05T00:00:00.000Z","title":"Lilly says retatrutide data package is complete, plans Q1 2027 filing","status":"confirmed","cites":[{"id":"metabolic-medicine-retatrutide-bla-plan","n":7,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm","publisher":"Eli Lilly and Company (SEC filing)","short":"Eli Lilly and Company"}]},{"id":"k8cbra","at":"2026-08-04T00:00:00.000Z","title":"Novo Nordisk raises 2026 outlook on stronger GLP-1 demand","status":"confirmed","cites":[{"id":"metabolic-medicine-novo-2026-outlook","n":45,"url":"https://www.sec.gov/Archives/edgar/data/353278/000117184326005184/f6k_080426.htm","publisher":"Novo Nordisk (SEC filing)","short":"Novo Nordisk"},{"id":"metabolic-medicine-wegovy-pill-uptake","n":14,"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm","publisher":"Novo Nordisk (SEC filing)","short":"Novo Nordisk"}]},{"id":"uz1t14","at":"2026-07-01T00:00:00.000Z","title":"Medicare GLP-1 Bridge begins offering obesity drugs for $50 a month","status":"confirmed","cites":[{"id":"metabolic-medicine-medicare-bridge","n":4,"url":"https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries","publisher":"Centers for Medicare & Medicaid Services","short":"Centers for Medicare…"},{"id":"metabolic-medicine-bridge-live","n":44,"url":"https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm","publisher":"Novo Nordisk (SEC filing)","short":"Novo Nordisk"}]},{"id":"1kadz9j","at":"2026-06-07T00:00:00.000Z","title":"CagriSema REIMAGINE 3 results in insulin-treated type 2 diabetes published in The Lancet","status":"confirmed","cites":[{"id":"metabolic-medicine-reimagine3-result","n":46,"url":"https://doi.org/10.1016/S0140-6736(26)01022-6","publisher":"The Lancet","short":"The Lancet"}]},{"id":"ztelvr","at":"2026-05-21T00:00:00.000Z","title":"Retatrutide shows 28.3% average weight loss in phase 3 TRIUMPH-1 (company topline)","status":"reported","cites":[{"id":"metabolic-medicine-triumph1-result","n":9,"url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html","publisher":"Eli Lilly and Company (press release via PR Newswire)","short":"Eli Lilly and Company"}]},{"id":"s81110","at":"2026-05-13T00:00:00.000Z","title":"ATTAIN-MAINTAIN shows orforglipron pill preserves most weight lost on injections","status":"confirmed","cites":[{"id":"metabolic-medicine-attain-maintain-result","n":25,"url":"https://doi.org/10.1038/s41591-026-04386-7","publisher":"Nature Medicine","short":"Nature Medicine"}]},{"id":"sxza43","at":"2026-04-30T00:00:00.000Z","title":"FDA proposes ending bulk compounding of semaglutide and tirzepatide by outsourcing facilities","status":"confirmed","cites":[{"id":"metabolic-medicine-fda-503b-proposal","n":28,"url":"https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"snzwhb","at":"2026-04-01T00:00:00.000Z","title":"FDA approves Lilly's orforglipron (Foundayo) pill","status":"confirmed","cites":[{"id":"metabolic-medicine-foundayo-approval","n":3,"url":"https://www.healio.com/news/endocrinology/20260401/fda-approves-orforglipron-an-oral-glp1-for-adults-with-obesity","publisher":"Healio","short":"Healio"}]},{"id":"eppzu9","at":"2026-02-23T00:00:00.000Z","title":"CagriSema misses non-inferiority against tirzepatide in REDEFINE 4","status":"confirmed","cites":[{"id":"metabolic-medicine-redefine4-result","n":43,"url":"https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-redefine-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved","publisher":"Novo Nordisk (company announcement via BioSpace)","short":"Novo Nordisk"}]},{"id":"xeub9k","at":"2025-12-22T00:00:00.000Z","title":"FDA approves the Wegovy pill, first oral GLP-1 for weight management","status":"confirmed","cites":[{"id":"metabolic-medicine-wegovy-pill-approval","n":2,"url":"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472","publisher":"Novo Nordisk","short":"Novo Nordisk"}]},{"id":"10sis05","at":"2025-12-01T00:00:00.000Z","title":"WHO issues first guideline on GLP-1 medicines for obesity","status":"confirmed","cites":[{"id":"metabolic-medicine-who-guideline","n":42,"url":"https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity","publisher":"World Health Organization","short":"World Health Organization"}]},{"id":"erhun7","at":"2025-11-25T00:00:00.000Z","title":"Medicare negotiated price of $274 set for semaglutide, effective 2027","status":"confirmed","cites":[{"id":"metabolic-medicine-medicare-negotiated-price","n":16,"url":"https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf","publisher":"Centers for Medicare & Medicaid Services","short":"Centers for Medicare…"}]},{"id":"4e092o","at":"2025-11-24T00:00:00.000Z","title":"Semaglutide fails to slow Alzheimer's disease in evoke trials","status":"confirmed","cites":[{"id":"metabolic-medicine-evoke-result","n":41,"url":"https://www.sec.gov/Archives/edgar/data/353278/000117184325007519/f6k_112425.htm","publisher":"Novo Nordisk (SEC filing)","short":"Novo Nordisk"}]},{"id":"1mcjpfb","at":"2025-11-06T00:00:00.000Z","title":"White House pricing agreement with Lilly and Novo sets $245 Medicare price","status":"confirmed","cites":[{"id":"metabolic-medicine-mfn-deal","n":15,"url":"https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/","publisher":"The White House","short":"The White House"}]},{"id":"94n4it","at":"2025-08-15T00:00:00.000Z","title":"Wegovy gets accelerated approval for MASH with fibrosis","status":"confirmed","cites":[{"id":"metabolic-medicine-wegovy-mash-approval","n":11,"url":"https://www.sec.gov/Archives/edgar/data/353278/000117184325005454/f6k_081525.htm","publisher":"Novo Nordisk (SEC filing)","short":"Novo Nordisk"}]},{"id":"10lxjx0","at":"2025-02-21T00:00:00.000Z","title":"FDA declares US semaglutide shortage resolved","status":"confirmed","cites":[{"id":"metabolic-medicine-semaglutide-shortage-resolved","n":40,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"4l0ou8","at":"2025-01-28T00:00:00.000Z","title":"Ozempic label expanded to kidney disease in type 2 diabetes, based on FLOW","status":"confirmed","cites":[{"id":"metabolic-medicine-ozempic-ckd-approval","n":10,"url":"https://www.kidney.org/news-stories/fda-approves-ozempic-type-2-diabetes-and-chronic-kidney-disease","publisher":"National Kidney Foundation","short":"National Kidney Foundation"},{"id":"metabolic-medicine-flow-result","n":39,"url":"https://europepmc.org/article/MED/38785209","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"1aqz55r","at":"2025-01-14T00:00:00.000Z","title":"Lancet Commission defines \"clinical\" and \"preclinical\" obesity","status":"confirmed","cites":[{"id":"metabolic-medicine-lancet-clinical-obesity","n":37,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/","publisher":"The Lancet Diabetes & Endocrinology","short":"The Lancet Diabetes…"},{"id":"metabolic-medicine-lancet-endorsement","n":38,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/","publisher":"The Lancet Diabetes & Endocrinology","short":"The Lancet Diabetes…"}]},{"id":"uyqex3","at":"2024-12-20T00:00:00.000Z","title":"Zepbound becomes first drug approved for obstructive sleep apnea","status":"confirmed","cites":[{"id":"metabolic-medicine-zepbound-osa-approval","n":13,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"8dslrg","at":"2024-12-19T00:00:00.000Z","title":"FDA declares US tirzepatide shortage resolved","status":"confirmed","cites":[{"id":"metabolic-medicine-tirzepatide-shortage-resolved","n":36,"url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]},{"id":"1xkd75f","at":"2024-03-08T00:00:00.000Z","title":"Wegovy approved to cut cardiovascular risk, based on SELECT","status":"confirmed","cites":[{"id":"metabolic-medicine-fda-wegovy-cv","n":1,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"},{"id":"metabolic-medicine-select-result","n":33,"url":"https://europepmc.org/article/MED/37952131","publisher":"The New England Journal of Medicine","short":"The New England Journal…"}]},{"id":"16l0d92","at":"2023-11-08T00:00:00.000Z","title":"FDA approves Zepbound (tirzepatide) for chronic weight management","status":"confirmed","cites":[{"id":"metabolic-medicine-zepbound-approval","n":35,"url":"https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management","publisher":"U.S. Food and Drug Administration","short":"U.S. Food and Drug…"}]}]}